US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Sanofi

95.32

+1.571.67%

Volume:246.00

Turnover:23.62K

Market Cap:116.24B

PE:17.48

High:95.32

Open:95.32

Low:95.32

Close:93.75

52wk High:122.03

52wk Low:90.05

Shares:1.22B

Float Shares:1.10B

Volume Ratio:0.01

T/O Rate:0.00%

Dividend:4.60

Dividend Rate:4.83%

EPS(TTM):5.45

EPS(LYR):4.60

ROE:6.66%

ROA:4.65%

PB:1.38

PE(LYR):20.72

Loading ...

Overview Company News Filings

Sanofi Consumer Healthcare India Clears FY25 Results, Proposes Rs 75 Final Dividend

Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

Benzinga_recent_news

Sanofi’s New Pediatric Fitusiran Trial Signals a Long-Term Hemophilia Push

Regeneron, Sanofi announce FDA approval of Dupixent for AFRS

Sanofi Real-World Data Show Durable Two-Season Protection From Beyfortus in Infants

Sanofi price target lowered to EUR 80 from EUR 85 at Citi

Sanofi Sued by Texas Attorney General Over Alleged Provider 'Bribery'

MT Newswires Live

Sanofi’s Real-World COPD Study on Dupilumab: What Investors Should Watch

Sanofi Wins U.S. Breakthrough and Japan Orphan Status for Rilzabrutinib in Rare Anemia

Press Release: Sanofi announces leadership evolution in Specialty Care Business Unit

Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Karyopharm Therapeutics (KPTI)

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

European Stocks Mixed in Thursday Trading; Sanofi Names Belen Garijo as CEO

MT Newswires Live

Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial

Sanofi Names Belén Garijo as New CEO, Effective After April Shareholder Meeting

Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'

Sanofi ‘decides not to renew’ mandate of CEO Paul Hudson

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNYNF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNYNF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNYNF\",,,,,undefined,":{"symbol":"SNYNF","market":"US","secType":"STK","nameCN":"Sanofi","latestPrice":95.32,"timestamp":1772050205420,"preClose":93.75,"halted":0,"volume":246,"delay":15,"changeRate":0.016746666666666594,"floatShares":1098441430,"shares":1219473844,"eps":5.452053,"marketStatus":"Post-Mkt","change":1.57,"latestTime":"02-25 15:10:05 EST Delay","open":95.32,"high":95.32,"low":95.32,"amount":23617.112000000005,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":5.452053,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772067600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":93.75,"volumeRatio":0.005452},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNYNF\",,,,,undefined,":{"symbol":"SNYNF","floatShares":1098441430,"roa":"4.65%","roe":"6.66%","lyrEps":4.599879,"volumeRatio":0.005452,"shares":1219473844,"dividePrice":4.6031,"high":95.32,"amplitude":0,"preClose":93.75,"low":95.32,"week52Low":90.05,"pbRate":"1.38","psRate":"2.11","week52High":122.028,"institutionHeld":0,"latestPrice":95.32,"eps":5.452053,"divideRate":0.048291,"volume":246,"delay":15,"ttmEps":5.452053,"open":95.32,"prevYearClose":97.295,"prevWeekClose":95.04,"prevMonthClose":91.11,"prevQuarterClose":97.295,"fiveDayClose":92.03,"twentyDayClose":94.993,"sixtyDayClose":100},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNYNF\",params:#limit:5,,,undefined,":[{"date":"2025-05-12","symbol":"SNYNF","amount":3.92,"announcedDate":"2025-01-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-13","defaultRemindTime":1747056600000,"name":"Sanofi","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-14","payableDate":"2025-05-13","currency":"EUR","dateTimestamp":1747022400000,"payDate":"2025-05-14"},{"date":"2024-05-13","symbol":"SNYNF","amount":3.76,"announcedDate":"2024-02-01","type":"dividend","market":"US","newRecordDate":"2024-05-14","defaultRemindTime":1715607000000,"name":"Sanofi","recordDate":"2024-05-15","payableDate":"2024-05-14","currency":"EUR","dateTimestamp":1715572800000,"payDate":"2024-05-15"},{"market":"US","date":"2024-04-25","symbol":"SNYNF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"pre","actualEps":null},{"date":"2023-05-30","symbol":"SNYNF","amount":3.56,"announcedDate":"2023-02-03","type":"dividend","market":"US","newRecordDate":"2023-05-31","defaultRemindTime":1685453400000,"name":"Sanofi","recordDate":"2023-06-01","payableDate":"2023-05-31","currency":"EUR","dateTimestamp":1685419200000,"payDate":"2023-06-01"},{"date":"2022-10-28","symbol":"SNYNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1666944000000,"name":null,"time":"Pre-Market","dateTimestamp":1666929600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNYNF\",market:\"US\",,,undefined,":[{"executeDate":"2019-05-09","recordDate":"2019-05-10","paymentDate":"2019-05-13","value":3.07,"currency":"EUR"},{"executeDate":"2020-05-04","recordDate":"2020-05-05","paymentDate":"2020-05-06","value":3.15,"currency":"EUR"},{"executeDate":"2021-05-05","recordDate":"2021-05-06","paymentDate":"2021-05-07","value":3.2,"currency":"EUR"},{"executeDate":"2022-05-06","recordDate":"2022-05-09","paymentDate":"2022-05-10","value":3.33,"currency":"EUR"},{"executeDate":"2023-05-30","recordDate":"2023-05-31","paymentDate":"2023-06-01","value":3.56,"currency":"EUR"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNYNF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNYNF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614171036","title":"Sanofi Consumer Healthcare India Clears FY25 Results, Proposes Rs 75 Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2614171036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614171036?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:13","pubTimestamp":1772032416,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Sanofi Consumer Healthcare India Limited ( ($IN:SANOFICONR) ). Sanofi Consumer Healthcare India Limited’s board...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofi-consumer-healthcare-india-clears-fy25-results-proposes-rs-75-final-dividend?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofi-consumer-healthcare-india-clears-fy25-results-proposes-rs-75-final-dividend?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4581","BK4137","SNYNF","XLV","MNDmain","LU0128526141.USD","BK4585","LU0029874061.USD","XBI","BK4588","LABU","HCSG"],"gpt_icon":0},{"id":"2614744498","title":"Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2614744498","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614744498?lang=en_us&edition=fundamental","pubTime":"2026-02-25 02:47","pubTimestamp":1771958820,"startTime":"0","endTime":"0","summary":"FDA approves Regeneron and Sanofi's Dupixent for allergic fungal sinusitis in patients 6 years and older with prior surgery history.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/24/Blue-3d-Graphic-Of-A-Woman-With-Sinus-Pa.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/24/Blue-3d-Graphic-Of-A-Woman-With-Sinus-Pa.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/02/50827647/regeneron-sanofi-blockbuster-dupixent-scores-fda-nod-for-rare-sinus-condition","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/02/50827647/regeneron-sanofi-blockbuster-dupixent-scores-fda-nod-for-rare-sinus-condition","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","SNYNF","SMA","BK4217"],"gpt_icon":0},{"id":"2614328746","title":"Sanofi’s New Pediatric Fitusiran Trial Signals a Long-Term Hemophilia Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2614328746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614328746?lang=en_us&edition=fundamental","pubTime":"2026-02-25 00:30","pubTimestamp":1771950659,"startTime":"0","endTime":"0","summary":"Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi Expands Pediatric Hemophilia Bet With New Fitusiran Phase 3 Study The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofis-new-pediatric-fitusiran-trial-signals-a-long-term-hemophilia-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofis-new-pediatric-fitusiran-trial-signals-a-long-term-hemophilia-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF","BK4007"],"gpt_icon":0},{"id":"2613710794","title":"Regeneron, Sanofi announce FDA approval of Dupixent for AFRS","url":"https://stock-news.laohu8.com/highlight/detail?id=2613710794","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613710794?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:35","pubTimestamp":1771943734,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-sanofi-announce-fda-approval-of-dupixent-for-afrs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-sanofi-announce-fda-approval-of-dupixent-for-afrs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2023250504.SGD","LU2362541513.USD","LU2089984988.USD","SNYNF","LU0823434740.USD","BK4585","LU0882574055.USD","LU0823434583.USD","LU0289739699.SGD","LU1917777945.USD","BK4007","IE00BFXG1179.USD","LU0114720955.EUR","BK4588","SNY","LU0823416689.USD","LU0109394709.USD","LU2106854487.HKD","LU0320765992.SGD","LU0889565916.HKD","LU0058720904.USD","LU2362540622.SGD","LU0053666078.USD","REGN","BK4139","LU1974910355.USD","LU2468319806.SGD","LU2362541273.HKD","LU2237438978.USD"],"gpt_icon":0},{"id":"2613333217","title":"Sanofi Real-World Data Show Durable Two-Season Protection From Beyfortus in Infants","url":"https://stock-news.laohu8.com/highlight/detail?id=2613333217","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613333217?lang=en_us&edition=fundamental","pubTime":"2026-02-23 23:20","pubTimestamp":1771860051,"startTime":"0","endTime":"0","summary":"Sanofi ( ($SNY) ) just unveiled an announcement. In February 2026, Sanofi highlighted new real-world data on its RSV antibody Beyfortus, showing st...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofi-real-world-data-show-durable-two-season-protection-from-beyfortus-in-infants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofi-real-world-data-show-durable-two-season-protection-from-beyfortus-in-infants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SNYNF"],"gpt_icon":0},{"id":"2613296748","title":"Sanofi price target lowered to EUR 80 from EUR 85 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2613296748","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613296748?lang=en_us&edition=fundamental","pubTime":"2026-02-21 01:12","pubTimestamp":1771607550,"startTime":"0","endTime":"0","summary":"Citi lowered the firm’s price target on Sanofi (SNY) to EUR 80 from EUR 85 and keeps a Neutral rating on the shares. Published first on TheFly – th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sanofi-price-target-lowered-to-eur-80-from-eur-85-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sanofi-price-target-lowered-to-eur-80-from-eur-85-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF"],"gpt_icon":0},{"id":"2612426129","title":"Sanofi Sued by Texas Attorney General Over Alleged Provider 'Bribery'","url":"https://stock-news.laohu8.com/highlight/detail?id=2612426129","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612426129?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:16","pubTimestamp":1771589790,"startTime":"0","endTime":"0","summary":"Sanofi  has been sued by Texas Attorney General Ken Paxton over allegations that it offers improper incentives to healthcare providers to prescribe its drugs.The Texas Attorney General's Office said Sanofi created programs that offered services to healthcare providers which amounted to bribes under the Texas Health Care Program Fraud Prevention Act.Paxton is seeking more than $1 million in monetary relief, including civil penalties, as well as an injunction to halt any alleged unlawful conduct, the Attorney General's Office added.Sanofi said the complaint mischaracterizes legitimate patient support programs, including nurse education and reimbursement assistance services.The company added that the programs comply with federal and state laws.\"The state's intervention has no bearing on the merits of this case, and Sanofi is zealously defending this litigation,\" the drugmaker said in an emailed statement.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFXG1179.USD","SNYNF","SNY","BK4588","BK4007","BK4585"],"gpt_icon":0},{"id":"2612669714","title":"Sanofi’s Real-World COPD Study on Dupilumab: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2612669714","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612669714?lang=en_us&edition=fundamental","pubTime":"2026-02-18 00:30","pubTimestamp":1771345855,"startTime":"0","endTime":"0","summary":"Sanofi SA ($SNY) announced an update on their ongoing clinical study. The study “Prospective and Retrospective Observational Real-world Study to Ch...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofis-real-world-copd-study-on-dupilumab-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofis-real-world-copd-study-on-dupilumab-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF","ISBC","BK4007","BK4211"],"gpt_icon":0},{"id":"2612463365","title":"Sanofi Wins U.S. Breakthrough and Japan Orphan Status for Rilzabrutinib in Rare Anemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2612463365","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612463365?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:57","pubTimestamp":1771340246,"startTime":"0","endTime":"0","summary":"Sanofi ( ($SNY) ) just unveiled an update. On February 9, 2026, Sanofi announced that its oral BTK inhibitor rilzabrutinib, marketed as Wayrilz for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofi-wins-u-s-breakthrough-and-japan-orphan-status-for-rilzabrutinib-in-rare-anemia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofi-wins-u-s-breakthrough-and-japan-orphan-status-for-rilzabrutinib-in-rare-anemia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SNYNF"],"gpt_icon":0},{"id":"2612457196","title":"Press Release: Sanofi announces leadership evolution in Specialty Care Business Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2612457196","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612457196?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:30","pubTimestamp":1771335000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity.Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0320765646.SGD","BK4232","SNY","LU1829250122.USD","BK4585","BK4588","BP","SNYNF","IE00BFXG1179.USD","BK4201","R","LU0162691827.USD","PN","LU1162221912.USD","BK4096","BK4022","LU0072461881.USD"],"gpt_icon":0},{"id":"2612456221","title":"Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s","url":"https://stock-news.laohu8.com/highlight/detail?id=2612456221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612456221?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:16","pubTimestamp":1771326961,"startTime":"0","endTime":"0","summary":"Teva (TEVA) and Sanofi (SNY) announced positive results from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human mono...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-and-sanofis-duvakitug-phase-2b-data-shows-efficacy-in-colitis-and-crohns-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-and-sanofis-duvakitug-phase-2b-data-shows-efficacy-in-colitis-and-crohns-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","IE00BFXG1179.USD","BK4584","BK4557","BK4596","LU1983299246.USD","TEVA","BK4559","BK4007","SNY","BK4588","SNYNF","BK4585","LU2324357040.USD"],"gpt_icon":0},{"id":"2612451743","title":"Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2612451743","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612451743?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:00","pubTimestamp":1771326000,"startTime":"0","endTime":"0","summary":"In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well toler","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239015/0/en/Teva-and-Sanofi-s-duvakitug-phase-2b-maintenance-data-demonstrated-clinically-meaningful-durable-efficacy-in-ulcerative-colitis-and-Crohn-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNYNF","IBD","CD","BK4023","BK4116","BK4007"],"gpt_icon":0},{"id":"2611978131","title":"Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Karyopharm Therapeutics (KPTI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611978131","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611978131?lang=en_us&edition=fundamental","pubTime":"2026-02-14 09:50","pubTimestamp":1771033807,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Karyopharm Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-and-karyopharm-therapeutics-kpti-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-and-karyopharm-therapeutics-kpti-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0128526141.USD","HCSG","LU0029874061.USD","SNYNF","XBI","BK4585","XLV","BK4139","KPTI","BK4137","BK4581","LABU","BK4007"],"gpt_icon":0},{"id":"2611150807","title":"Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2611150807","media":"Benzinga","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611150807?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:23","pubTimestamp":1770988980,"startTime":"0","endTime":"0","summary":"Sanofi shares drop after CEO exit and pipeline concerns grow, even as Dupixent sales jump in latest quarter.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/13/Sanofi-SA.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/13/Sanofi-SA.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50607808/sanofi-stock-near-52-week-low-as-leadership-shakeup-rattles-investors","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/02/50607808/sanofi-stock-near-52-week-low-as-leadership-shakeup-rattles-investors","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU2023250504.SGD","LU2362541513.USD","LU2089984988.USD","SNYNF","LU0823434740.USD","BK4585","LU0882574055.USD","LU0823434583.USD","LU0289739699.SGD","LU1917777945.USD","BK4007","IE00BFXG1179.USD","LU0114720955.EUR","BK4211","BK4588","SNY","BK4217","ISBC","LU0823416689.USD","LU0109394709.USD","LU2106854487.HKD","SMA","LU0320765992.SGD","LU0889565916.HKD","LU0058720904.USD","LU2362540622.SGD","LU0053666078.USD","REGN","BK4139","LU1974910355.USD","LU2468319806.SGD","LU2362541273.HKD","LU2237438978.USD"],"gpt_icon":0},{"id":"2611422131","title":"Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2611422131","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611422131?lang=en_us&edition=fundamental","pubTime":"2026-02-13 16:21","pubTimestamp":1770970860,"startTime":"0","endTime":"0","summary":"0820 GMT - Sanofi's abrupt move to replace CEO Paul Hudson with Merck KGaA's head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. \"We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take.\" Shares are down 0.6% at 78.59 euros. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY","SNYNF","BK4585","IE00BFXG1179.USD","BK4007","BK4588"],"gpt_icon":0},{"id":"2611976378","title":"European Stocks Mixed in Thursday Trading; Sanofi Names Belen Garijo as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2611976378","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611976378?lang=en_us&edition=fundamental","pubTime":"2026-02-13 01:04","pubTimestamp":1770915896,"startTime":"0","endTime":"0","summary":"The European stock markets were mixed in Thursday trading as The Stoxx Europe declined 0.6%, Germany's DAX was down 0.1%, the FTSE 100 was off 0.7%, France's CAC rose 0.3%, and the Swiss Market Index ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","SNYNF"],"gpt_icon":0},{"id":"2611975300","title":"Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2611975300","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611975300?lang=en_us&edition=fundamental","pubTime":"2026-02-13 00:30","pubTimestamp":1770913824,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi and Regeneron are running a proof-of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofi-and-regeneron-advance-itepekimab-bet-with-completed-phase-2-bronchiectasis-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofi-and-regeneron-advance-itepekimab-bet-with-completed-phase-2-bronchiectasis-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF","BK4007"],"gpt_icon":0},{"id":"2610927033","title":"Sanofi Names Belén Garijo as New CEO, Effective After April Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2610927033","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610927033?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:49","pubTimestamp":1770907756,"startTime":"0","endTime":"0","summary":"An announcement from Sanofi ( ($SNY) ) is now available. Sanofi announced on February 12, 2026, that its Board of Directors decided on February 11 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofi-names-belen-garijo-as-new-ceo-effective-after-april-shareholder-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofi-names-belen-garijo-as-new-ceo-effective-after-april-shareholder-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF","BK4007"],"gpt_icon":0},{"id":"2610448940","title":"Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'","url":"https://stock-news.laohu8.com/highlight/detail?id=2610448940","media":"Benzinga","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610448940?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:28","pubTimestamp":1770895680,"startTime":"0","endTime":"0","summary":"Sanofi SA  on Wednesday decided not to renew the Director mandate of Paul Hudson.As a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his tenure of six years with the company.The Board of Directors appointed Belén Garijo as Chief Executive Officer. She will take up her duties at the end of the Group’s Annual General Meeting on April 29, 2026. The Board will also propose to the shareholder vote the candidacy of Belén Garijo as a director of the Group.Olivier Charmeil, Executive Vice President, General Medicines, will assume the role of Interim Chief Executive Officer during this transition.Belén Garijo will bring an increased rigor to the implementation of Sanofi’s strategy and accelerate the preparation of the Group’s future. Her priority will be to strengthen the productivity, governance, and innovation capacity of Research & Development.Reuters noted that the abrupt transition, underscoring rising pressure on Sanofi from U.S. vaccine head","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/12/Gentilly--France--March-21--2021-Sign-An.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/12/Gentilly--France--March-21--2021-Sign-An.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/large-cap/26/02/50569675/sanofi-shocker-ceo-paul-hudson-out-as-board-demands-increased-rigor","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/26/02/50569675/sanofi-shocker-ceo-paul-hudson-out-as-board-demands-increased-rigor","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","SNYNF","HUDAU","PPH","BK4132","SNY","BK4588","BK4585","IE00BFXG1179.USD","AD"],"gpt_icon":0},{"id":"2610947229","title":"Sanofi ‘decides not to renew’ mandate of CEO Paul Hudson","url":"https://stock-news.laohu8.com/highlight/detail?id=2610947229","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610947229?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:05","pubTimestamp":1770894359,"startTime":"0","endTime":"0","summary":"Sanofi’s (SNY) Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson. As a result, Paul Hudson’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sanofi-decides-not-to-renew-mandate-of-ceo-paul-hudson-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sanofi-decides-not-to-renew-mandate-of-ceo-paul-hudson-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFXG1179.USD","SNY","BK4007","HUDAU","BK4585","BK4588","SNYNF"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":193,"code":"91000000","status":"200"}]}}